Regeneron Pharmaceuticals, Inc. (0R2M.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
As of 02:55PM BST. Market open.
| Previous close | 892.94 |
| Open | 894.53 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 885.00 - 894.53 |
| 52-week range | 689.00 - 998.57 |
| Volume | |
| Avg. volume | 1,962 |
| Market cap | 985.518M |
| Beta (5Y monthly) | 0.14 |
| PE ratio (TTM) | 0.13 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?
An increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided Regeneron (REGN) in partially offsetting the decline in Eylea sales.
- Zacks
Down -8.24% in 4 Weeks, Here's Why Regeneron (REGN) Looks Ripe for a Turnaround
Regeneron (REGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- Zacks
Countdown to Regeneron (REGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of Regeneron (REGN) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
© 2024 Yahoo. All rights reserved.